The Prior Authorization Process for TMS: A Step-by-Step Patient Walkthrough

Prior authorization for transcranial magnetic stimulation typically takes 5 to 15 business days for commercial-payer review, or 7 calendar days for standard review and 72 hours for expedited review under Medicare Advantage, Medicaid, and Federally-Facilitated Exchange marketplace plans subject to CMS-0057-F.¹ The prior-authorization step is the most opaque part of the TMS treatment pathway for most patients, and the most common source of pre-treatment delay. This article walks through what prior authorization is, the clinical criteria the payer is reviewing, the documentation packet the clinic submits, what happens when a decision is delayed or denied, and how the appeals process — including California's Independent Medical Review — actually works.

What prior authorization is, and why it exists for TMS

Prior authorization (PA) is a payer's written, pre-treatment review of medical necessity: a determination, made before any sessions are billed, that the proposed TMS therapy meets the carrier's documented criteria for coverage. For TMS, prior authorization is required by most major commercial payers and by Medicare. Treatment delivered without it is generally not reimbursed, regardless of clinical appropriateness.

The framework is regulatory rather than discretionary. Medicare coverage for TMS is governed by Local Coverage Determinations (LCDs) issued by the Medicare Administrative Contractors — for example, Noridian LCD L34522 and Palmetto LCD L34869. CMS has not issued a National Coverage Determination for TMS, so the specific criteria a Medicare beneficiary must meet depend on the MAC for their geography.² Commercial-payer policies are typically modeled on the same evidentiary base — the FDA-cleared indication language for the original device, the NeuroStar Advanced Therapy System under 510(k) K061053, which describes treatment of major depressive disorder in adults who have failed to achieve satisfactory improvement from prior antidepressant medication.³ The Clinical TMS Society consensus recommendations remain the device-agnostic clinical reference for protocol and parameter selection.⁴

The clinical eligibility criteria the payer is reviewing

A prior-authorization reviewer is checking the submitted record against a checklist that, in broad terms, looks the same across most commercial and Medicare policies. Expect criteria along these lines:

• A DSM-5-TR diagnosis of major depressive disorder, single or recurrent episode, confirmed by a psychiatrist or qualified mental-health prescriber.
• A current depressive episode of at least moderate-to-severe severity, evidenced by a validated rating scale — payers most commonly require a PHQ-9 ≥20, a HAM-D ≥24, or a MADRS ≥35.
• Documented failure of at least two adequate antidepressant trials in the current episode, from at least two distinct pharmacologic classes. This is the criterion that aligns most directly with the FDA-cleared indication language for TMS in adults.³
• Adequate trial = therapeutic dose × at least six weeks. Trials at sub-therapeutic dose or discontinued before six weeks generally do not count toward the failed-trial requirement.
• Often, an adequate trial of evidence-based psychotherapy — typically cognitive-behavioral therapy or interpersonal therapy — of adequate duration, or documented clinical reason psychotherapy is not appropriate or accessible.
• No clinical contraindication to TMS. The most relevant contraindications are personal history of seizure disorder, ferromagnetic implants within approximately 30 cm of the treatment coil, and certain implanted neurostimulation or cochlear devices.

Carrier-specific add-ons appear at the margins — additional augmentation trials, lifetime medication-trial counts, or specific psychotherapy-modality requirements — but the core criteria above are common to virtually every payer policy in the United States. Patients with a clinical picture consistent with treatment-resistant depression generally meet the criteria; the question prior authorization is answering is whether the record documents it adequately, not whether the patient is clinically appropriate.

The documentation packet the clinic submits

A complete PA submission for TMS typically consists of:

• PHQ-9 (or equivalent) scores at intake and, where available, serially across the current episode — establishing baseline severity and trajectory.
• A treatment-history letter from the treating psychiatrist summarizing the diagnosis, the current episode, the failed pharmacologic trials, and the clinical rationale for proceeding to TMS.
• A medication-trial log for the current episode — each antidepressant tried, dose, start and stop dates, duration at therapeutic dose, reason for discontinuation (non-response, side effects, intolerance), and the prescribing clinician.
• Evidence of psychotherapy during the current episode where required by policy — clinician name, modality, frequency, and dates — or a documented clinical reason psychotherapy is not appropriate.
• A treatment plan specifying the requested protocol (10 Hz rTMS, intermittent theta-burst stimulation, or other FDA-cleared protocol), the proposed session count for the acute phase, the planned taper, and the treating psychiatrist's signature.
• A statement of candidacy confirming the absence of contraindications, derived from the candidacy evaluation.

A complete packet at first submission is the single largest determinant of turnaround time. Incomplete packets — most commonly missing medication-trial dates or rating-scale evidence — are the leading cause of decision delays and the leading correctable cause of initial denials.

Timelines: what to expect, by plan type

Turnaround time depends on the type of plan and on whether expedited review is appropriate.

Commercial and ERISA plans

Most commercial fully-insured plans and self-funded ERISA plans not otherwise covered by the CMS rule below operate on internal turnaround standards that, in practice, run 5 to 15 business days for standard prior-authorization review for TMS. Some plans contract behavioral-health prior authorization to a separate utilization-review vendor; that detail is captured at insurance verification, not at the time of PA submission.

Medicare Advantage, Medicaid, CHIP, and Federally-Facilitated Exchange QHPs

Under the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), effective 2026, the affected payers — Medicare Advantage organizations, state Medicaid fee-for-service and managed-care plans, CHIP fee-for-service and managed-care plans, and Qualified Health Plan issuers on the Federally-Facilitated Exchanges — must issue prior-authorization decisions within 7 calendar days for standard review and 72 hours for expedited review.¹ Original Medicare (fee-for-service Parts A and B) generally does not require prior authorization for the TMS CPT codes; coverage is adjudicated at the claim under the applicable MAC LCD.²

Expedited review

Expedited review is appropriate where standard timeframes would seriously jeopardize the patient's life, health, or ability to regain maximum function. In the depression population, the typical clinical basis is active suicidality with documented prior-treatment failure — a situation in which a 7- to 15-day wait for review is itself a clinical risk. The treating psychiatrist documents the clinical urgency in the submission; the determination of whether expedited review is granted is the payer's.

When prior authorization is denied — the appeals path

A denial is not the end of the process. Most TMS denials are denials of documentation, not denials of clinical appropriateness, and the standard appeals path is structured to address that.

• Peer-to-peer review. The clinic's psychiatrist speaks directly with the payer's medical director or a designated reviewing physician. The conversation typically clarifies the medication-trial chronology or the psychotherapy criterion in a way the written submission did not. Peer-to-peer reviews reverse a meaningful share of initial denials and are typically the first appeal step.
• Formal written appeal. A written appeal supplements the original submission with additional documentation — clarifying medication-trial dates, supplying missing chart notes from outside prescribers, or providing additional rating-scale evidence. The appeal is reviewed by a physician other than the original reviewer, typically within 30 days for commercial plans and within the same CMS-0057-F timeframes for affected plans.
• External independent review. When internal appeals are exhausted, most states provide an external review by an independent physician panel not employed by the payer. The external reviewer's decision is binding on the payer in most states.

The California-specific path: Independent Medical Review

For patients covered by California-regulated commercial plans, the Independent Medical Review (IMR) process administered by the California Department of Managed Health Care (DMHC) is the external-review path for medical-necessity denials. After the plan's internal appeals are completed (or in cases of urgency, sometimes before), the patient or the clinic may submit an IMR application to DMHC; the file is reviewed by an independent physician panel contracted by DMHC, and the panel's decision is binding on the health plan.⁵ IMR is no cost to the patient. Health plans regulated by the California Department of Insurance (rather than DMHC — primarily PPO products underwritten by life or disability carriers) follow a parallel CDI external-review process. Medicare Advantage and self-funded ERISA plans follow their own external-review tracks rather than the DMHC IMR.

Continued-treatment authorization

The initial PA approval typically covers a specified number of sessions — most commonly the standard 36-session acute phase, sometimes with a defined taper, sometimes with a documented-response milestone. If the treating psychiatrist determines that additional sessions are clinically warranted — for example, ongoing measurable improvement that has not yet reached remission, or a clinical decision to extend the acute phase before declaring non-response — a continued-treatment authorization request is submitted separately. The packet for continued treatment is more compact than the initial PA: serial rating-scale evidence documenting trajectory, a letter of medical necessity from the treating psychiatrist describing the clinical rationale, and the updated treatment plan. Approval rates for continued-treatment authorization are generally high when serial response data are documented.

What the patient does, and what the clinic does

The administrative burden of prior authorization falls on the clinic, not the patient. The clinic's insurance team obtains and reviews benefits, assembles the documentation packet, submits to the payer, tracks the decision, conducts the peer-to-peer review if needed, and prepares any subsequent appeal. The patient's role is narrower:

• Providing accurate, current insurance information (front and back of the card, subscriber details if covered as a dependent).
• Signing the authorization-to-verify-benefits form that permits the clinic to contact the carrier on the patient's behalf.
• Providing accurate prior-prescriber information when the clinic requests records from outside psychiatrists or therapists.
• Continuing to attend any required appointments — diagnostic visits, rating-scale check-ins — during the PA window so that the record under review remains current.

Submitting insurance details through the insurance verification form is the standard starting point; once benefits are confirmed and the prior-authorization packet is prepared, the clinic submits and tracks the decision.

Key takeaways

• Prior authorization is a payer's pre-treatment determination that proposed TMS treatment meets the carrier's medical-necessity criteria; without it, TMS is not reimbursed by most major commercial payers or Medicare Advantage.
• The clinical criteria most payers apply are a DSM-5-TR MDD diagnosis, moderate-to-severe current episode, failure of at least two adequate antidepressant trials (therapeutic dose × ≥6 weeks) in the current episode, and often a documented psychotherapy trial.
• The documentation packet includes PHQ-9 scores, a treatment-history letter, a medication-trial log, evidence of psychotherapy where required, and a treatment plan specifying the requested protocol and session count.
• Standard turnaround is approximately 5 to 15 business days for commercial review and 7 calendar days standard / 72 hours expedited for plans subject to CMS-0057-F (Medicare Advantage, Medicaid, CHIP, FFE QHPs).
• Denials are appealable through peer-to-peer review, formal written appeal, and external independent review; California patients on DMHC-regulated plans have access to the Independent Medical Review process.
• The clinic carries the administrative work; the patient's role is providing accurate insurance information and signing the verification-of-benefits authorization.

For patients in Anaheim, Orange County, and the broader 30-mile radius, the clinic's team submits, tracks, and — if necessary — appeals the prior-authorization decision on the patient's behalf. The standard starting point is the insurance verification form; the TMS therapy page describes the clinical service the authorization is being sought for.

Sources / Further reading